Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| E2814 | Alzheimer's Disease (Phase 1/2) | Eisai Co., Ltd. | Tau | Immunotherapy (passive) | ||
| Gantenerumab | RO4909832, RG1450, R1450 |
Alzheimer's Disease (Discontinued) | Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | |
| Leqembi | Lecanemab-irmb, BAN2401, mAb158 |
Alzheimer's Disease (Approved) | BioArctic AB, Biogen, Eisai Co., Ltd. | Amyloid-Related | Immunotherapy (passive) | |
| LY2886721 | BACE inhibitor | Alzheimer's Disease (Discontinued), Mild Cognitive Impairment (Discontinued) | Eli Lilly & Co. | Amyloid-Related | Small Molecule | |
| Remternetug | LY3372993, N3pG-Abeta mAb |
Alzheimer's Disease (Phase 3) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | |
| Solanezumab | LY2062430 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | None |